We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02802943
Recruitment Status : Completed
First Posted : June 16, 2016
Last Update Posted : November 28, 2022
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Klinikum Stuttgart
Marienhospital Stuttgart
Katharinenhospital Stuttgart
Information provided by (Responsible Party):
University Hospital Tuebingen

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 30, 2022
Actual Study Completion Date : November 18, 2022